scholarly journals Frequency of Various Dermatoses Requiring Histopathological Evaluation For Definite Diagnosis; A Retrospective Analysis

Esculapio ◽  
2020 ◽  
Vol 16 (03, july 2020-Septmber 2020) ◽  
Author(s):  
Hira Tariq ◽  
Rabia Mukhtar ◽  
Abeer Fahad ◽  
Tariq Rashid ◽  
Ambereen Anwar ◽  
...  
Keyword(s):  
Connective Tissue ◽  
High Frequency ◽  
Connective Tissue Diseases ◽  
Histopathological Analysis ◽  
Definite Diagnosis ◽  
Drug Reactions ◽  
Histopathological Evaluation ◽  
Dermatological Disorders ◽  
Chronic Ulcers ◽  
Granulomatous Disorders

Objective: To assess the frequency of various dermatological disorders those require histopathological analysis for definite diagnosis. Methods: We included 669 patients of either gender and all ages in this retrospective study, carried out in the Department of Dermatology, Jinnah Hospital, Lahore for a duration of 2 years. Their clinical data and histopathological reports were analyzed. The dermatoses were categorized into (a) papulosquamous disorders, (b) bullous disorders, (c) eczemas, (d) neoplasia, (e) granulomatous disorders, (f) connective tissue diseases, (g) drug reactions, (h) vasculitides, (i) chronic ulcers and (j) miscellaneous disorders. Results: The frequency of various dermatoses noted were as follows: papulosquamous disorders 28.25%, bullous disorders 11.5%, granulomatous disorders 11.5%, connective tissue diseases 10.61%, miscellaneous disorders 10%, eczemas 9.4%, chronic ulcers 7.17 neoplasia 6.8%, vasculitides 2.84% and drug reactions were 1.79% of total biopsies. Conclusion: The frequency of different diagnostic groups was unique in some respects and confirmed to other studies in others. The significantly high frequency of papulosquamous disorders highlighted the importance of these disorders. Key words: Skin biopsy, papulosquamous disorders, bullous disorders, eczemas, neoplasia, granulomatous disorders, connective tissue diseases, drug reactions, vasculitides, chronic ulcers.

scholarly journals Histopathological evaluation of bone regeneration using human resorbable demineralized membrane

2010 ◽  
Vol 67 (6) ◽  
pp. 480-486
Author(s):  
Zoran Tatic ◽  
Novak Stamatovic ◽  
Marija Bubalo ◽  
Snezana Jancic ◽  
Alek Racic ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Connective Tissue ◽  
Bone Regeneration ◽  
Bone Tissue ◽  
Bone Defects ◽  
Histopathological Analysis ◽  
Bony Defect ◽  
Histopathological Evaluation ◽  
Bony Healing ◽  
The Right

Background/Aim. Filling a bone defect with bone substitution materials is a therapy of choice, but the infiltration of connective tissue from the mucoperiostal flap may compromise a healing of bone substitutions with bony wall defects. Application of membrane as a barrier is indicated as a solution to this problem. The aim of this study was to show a pathohistological view of bone regeneration and the significance of human resorbable demineralized membrane (HRDM), 200 ? thick in bone regeneration regarding mandibular defects in an experiment on dogs. Methods. The experiment was performed on six dogs. Bone defects were created in all six dogs on the right side of the mandible after the elevation of the mucoperiostal flap. One defect was filled with human deproteinised bone (HDB), and in between HDB and soft tissue RHDM of 200 ? thick was placed. In the second defect, used as a control one, only HDB without RHDM was placed. Two dogs were sacrificed two months after the surgery, another two dogs four months after the surgery and the last two dogs six months after the surgery. After that, samples of bone tissue were taken for histopathological analysis. Results. In all the six dogs with defects treated with HDB and RHDM the level of bone regeneration was much higher in comparison with the control defects without RHDM. Conclusion. Membrane, as a cover of bony defect, is useful and benefits bone regeneration. Bony defects covered with RHDM show better bony healing despite the fact that bone regeneration was not fully complete for as long as six months after the RHDM implantation.

scholarly journals Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide

2010 ◽  
Vol 2010 ◽  
pp. 1-2
Author(s):  
Marcelo Derbli Schafranski ◽  
Giuliano Doretto Campanari
Keyword(s):  
Connective Tissue ◽  
Female Patient ◽  
Connective Tissue Diseases ◽  
Cutaneous Vasculitis ◽  
Drug Reactions ◽  
History Of ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Caucasian Female

Cutaneous vasculitis can be classified as primary or idiopathic; or secondary, when it presents as a manifestation of connective tissue diseases, infections, drug reactions or malignancies. Although most of the idiopathic cases are self-limited and responsive to supportive measures and nonsteroidal anti-inflammatory drugs, potent immunosuppressants are sometimes required for the management of the refractory situations. Here we describe a case of a 32-year-old Caucasian female patient with history of idiopathic cutaneous deep vasculitis unresponsive to methotrexate, dapsone, and cyclophosphamide who was effectively treated with infliximab.

Abnormal Nailfold Capillaroscopy Is Common in Patients with Connective Tissue Disease and Associated with Abnormal Pulmonary Function Tests

2018 ◽  
Vol 46 (9) ◽  
pp. 1109-1116 ◽  
Author(s):  
Anniek M. van Roon ◽  
Cato C. Huisman ◽  
Arie M. van Roon ◽  
Dan Zhang ◽  
Alja J. Stel ◽  
...  
Keyword(s):  
Connective Tissue ◽  
Pulmonary Function ◽  
Connective Tissue Disease ◽  
Lupus Erythematosus ◽  
Pulmonary Function Tests ◽  
Connective Tissue Diseases ◽  
Definite Diagnosis ◽  
Predictive Values ◽  
Function Tests ◽  
Abnormal Pulmonary Function

Objective.To assess the presence of a systemic sclerosis (SSc) pattern on nailfold capillary microscopy (NCM) in patients with Raynaud phenomenon (RP) and to explore its association with abnormal pulmonary function tests (PFT).Methods.NCM patterns were assessed in 759 consecutive patients with RP. Patterns were classified as normal (n = 354), nonspecific (n = 159), or SSc pattern (n = 246). Abnormal PFT was defined as forced vital or diffusion capacity < 70%. Patients were classified as primary RP (n = 245), or secondary: no definite diagnosis (n = 391), SSc (n = 40), primary Sjögren syndrome (pSS; n = 30), systemic lupus erythematosus (SLE; n = 30), mixed connective tissue disease (MCTD; n = 7), rheumatoid arthritis (RA; n = 15).Results.An SSc pattern on NCM was frequently observed in most patients with a definite diagnosis: SSc (88%), pSS (33%), SLE (17%), MCTD (71%), and RA (13%). In patients without definite diagnosis, 17% had a normal NCM pattern, 35% nonspecific, and 48% SSc pattern. Abnormal PFT was more frequent in patients with an SSc pattern (35.9% vs 19.5%, p = 0.002), even when corrected for SSc diagnosis (p = 0.003). Absence of an SSc pattern had high negative predictive value (88%); positive predictive values were low.Conclusion.SSc pattern on NCM is common in patients with RP, and in those with connective tissue diseases other than SSc. It is associated with a higher prevalence of abnormal PFT, independent of the presence of an SSc diagnosis. Although these data need validation in a prospective setting, they underline the importance of NCM in RP and putative value to stratify the risk of pulmonary involvement in early stages of disease.

Non-infectious granulomatous disorders and connective tissue diseases

2021 ◽  
pp. 35-49
Author(s):  
Enzo Errichetti ◽  
Ahmed Sadek ◽  
Balachandra Ankad ◽  
Dalia Hossam ◽  
Abhijeet Kumar Jha ◽  
...  
Keyword(s):  
Connective Tissue ◽  
Connective Tissue Diseases ◽  
Granulomatous Disorders

scholarly journals Erythema multiforme in the dog

2018 ◽  
Vol 52 (3) ◽  
pp. 220
Author(s):  
C. PAITAKI (Χ. ΠΑΪΤΑΚΗ) ◽  
A. F. KOUTINAS (Α.Φ. ΚΟΥΤΙΝΑΣ) ◽  
M. N. SARIDOMICHELAKIS (Μ.Ν. ΣΑΡΙΔΟΜΙΧΕΛΑΚΗΣ)
Keyword(s):  
Connective Tissue ◽  
Hypersensitivity Reaction ◽  
Erythema Multiforme ◽  
Clinical Signs ◽  
Connective Tissue Diseases ◽  
Point Of View ◽  
Specific Cell ◽  
Definite Diagnosis ◽  
Clinical Point ◽  
Life Threatening

Canine erythema multiforme is a rarely seen skin eruption that is characterized by variable clinical signs and a rather distinctive histopathology. From a clinical point of view erythema multiforme is of particular interest, mainly due to its life-threatening potential. It is considered a host-specific cell-mediated hypersensitivity reaction, leading to epidermal and follicular wall keratinocyte apoptosis. Although the exact pathomechanism is not currently fully understood, it is often associated with drugs, infections, neoplastic and connective tissue diseases, adverse food reactions and idiopathy. Definite diagnosis is based on the clinical and histopathological findings and therapy aims to the elimination of the triggering factors and the institution of supportive measures. The usefulness of glucocorticoids in canine erythema multiforme is still controversial.

scholarly journals P170 The validity and utility of the SLE-key® rule-out serological test when applied in a selected cohort of patients with SLE and other connective tissue diseases

Rheumatology ◽  
2021 ◽  
Vol 60 (Supplement_1) ◽  
Author(s):  
Sheilla Achieng ◽  
John A Reynolds ◽  
Ian N Bruce ◽  
Marwan Bukhari
Keyword(s):  
Linear Regression ◽  
Connective Tissue ◽  
Connective Tissue Disease ◽  
Negative Correlation ◽  
Connective Tissue Diseases ◽  
Inflammatory Myositis ◽  
The Mean ◽  
Negative Rule ◽  
Spearman’S Correlation ◽  
Rule Out

Abstract Background/Aims  We aimed to establish the validity of the SLE-key® rule-out test and analyse its utility in distinguishing systemic lupus erythematosus (SLE) from other autoimmune rheumatic connective tissue diseases. Methods  We used data from the Lupus Extended Autoimmune Phenotype (LEAP) study, which included a representative cross-sectional sample of patients with a variety of rheumatic connective tissue diseases, including SLE, mixed connective tissue disease (MCTD), inflammatory myositis, systemic sclerosis, primary Sjögren’s syndrome and undifferentiated connective tissue disease (UCTD). The modified 1997 ACR criteria were used to classify patients with SLE. Banked serum samples were sent to Immune-Array’s CLIA- certified laboratory Veracis (Richmond, VA) for testing. Patients were assigned test scores between 0 and 1 where a score of 0 was considered a negative rule-out test (i.e. SLE cannot be excluded) whilst a score of 1 was assigned for a positive rule-out test (i.e. SLE excluded). Performance measures were used to assess the test’s validity and measures of association determined using linear regression and Spearman’s correlation. Results  Our study included a total of 155 patients of whom 66 had SLE. The mean age in the SLE group was 44.2 years (SD 13.04). 146 patients (94.1%) were female. 84 (54.2%) patients from the entire cohort had ACR SLE scores of ≤ 3 whilst 71 (45.8%) had ACR SLE scores ≥ 4. The mean ACR SLE total score for the SLE patients was 4.85 (SD 1.67), ranging from 2 to 8, with mean disease duration of 12.9 years. The Sensitivity of the SLE-Key® Rule-Out test in diagnosing SLE from other connective tissue diseases was 54.5%, specificity was 44.9%, PPV 42.4% and NPV 57.1 %. 45% of the SLE patients had a positive rule-out test. SLE could not be ruled out in 73% of the MCTD patients whilst 51% of the UCTD patients had a positive Rule-Out test and &gt;85% of the inflammatory myositis patients had a negative rule-out test. ROC analysis generated an AUC of 0.525 illustrating weak class separation capacity. Linear regression established a negative correlation between the SLE-key Rule-Out score and ACR SLE total scores. Spearman’s correlation was run to determine the relationship between ACR SLE total scores and SLE-key rule-out score and showed very weak negative correlation (rs = -0.0815, n = 155, p = 0.313). Conclusion  Our findings demonstrate that when applied in clinical practice in a rheumatology CTD clinic setting, the SLE-key® rule-out test does not accurately distinguish SLE from other CTDs. The development of a robust test that could achieve this would be pivotal. It is however important to highlight that the test was designed to distinguish healthy subjects from SLE patients and not for the purpose of differentiating SLE from other connective tissue diseases. Disclosure  S. Achieng: None. J.A. Reynolds: None. I.N. Bruce: Other; I.N.B is a National Institute for Health Research (NIHR) Senior Investigator and is funded by the NIHR Manchester Biomedical Research Centre. M. Bukhari: None.

Sign in / Sign up

Export Citation Format

Share Document